Trevi Therapeutics, Inc. - Common Stock (TRVI)
Frequently Asked Questions About Trevi Therapeutics, Inc. - Common Stock (TRVI)
Does Trevi Therapeutics have any patents?
Yes, Trevi Therapeutics holds several patents related to its drug formulations, treatment methods, and technologies. These intellectual property assets are crucial for protecting the company's innovations and competitive advantages in the biopharmaceutical market.
How can investors track Trevi Therapeutics' stock performance?
Investors can track Trevi Therapeutics' stock performance using various financial news websites, stock market apps, and brokerage platforms. The company's shares are traded under the ticker symbol TRVI on the Nasdaq, where investors can view historical data, current trading activity, and financial news updates.
How does Trevi Therapeutics address challenges in drug development?
Trevi Therapeutics addresses challenges in drug development through strategic planning, collaboration, and continuous evaluation of its research and development strategies. By engaging with regulatory authorities, utilizing innovative trial designs, and fostering scientific partnerships, the company aims to navigate the complexities of bringing a new drug to market efficiently.
How does Trevi Therapeutics approach drug development?
Trevi Therapeutics adopts a patient-centric approach to drug development, focusing on addressing the specific needs and experiences of patients suffering from chronic diseases. The company utilizes robust scientific research, innovative clinical trial designs, and collaboration with key stakeholders to enhance the likelihood of successful therapeutic outcomes.
How does Trevi Therapeutics ensure patient safety in its clinical trials?
Trevi Therapeutics prioritizes patient safety by adhering to strict regulatory guidelines and protocols during its clinical trials. The company conducts thorough assessments of its study designs and closely monitors participants for adverse effects while ensuring ethical standards are maintained throughout the research process.
Is Trevi Therapeutics involved in any partnerships?
Yes, Trevi Therapeutics actively seeks strategic collaborations and partnerships to enhance its research and development efforts. These collaborations often involve academic institutions, research organizations, or other pharmaceutical companies to share resources, technologies, and expertise necessary for advancing their drug candidates.
What are chronic cough and idiopathic pulmonary fibrosis?
Chronic cough is defined as a cough lasting more than eight weeks and can significantly impact a patient's quality of life. Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by scarring of the lung tissue, which leads to breathing difficulties. Patients with IPF may experience severe and persistent cough, making effective treatment crucial.
What are the future prospects for Trevi Therapeutics?
The future prospects for Trevi Therapeutics are promising as the company continues to make progress in its clinical trials, particularly with Haduvio. With a robust pipeline and a focus on addressing significant unmet medical needs, Trevi Therapeutics aims to bring innovative therapies to market, drive growth, and ultimately improve patient outcomes.
What does Trevi Therapeutics, Inc. do?
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutic solutions for patients suffering from unmet medical needs. The company's primary goal is to improve the quality of life for patients with neurological and dermatological conditions by developing novel drug candidates.
What financial support does Trevi Therapeutics have?
Trevi Therapeutics has garnered financial support through its initial public offering (IPO), subsequent funding rounds, and potential partnerships. These funds are critical for supporting the company's ongoing research and development initiatives, enabling it to advance its product candidates through clinical trials.
What is the main product candidate of Trevi Therapeutics?
Trevi Therapeutics is primarily focused on its lead product candidate, Haduvio (treprostinil), which is currently in clinical trials for the treatment of chronic cough associated with idiopathic pulmonary fibrosis (IPF) as well as other indications. Haduvio is designed to target specific receptors in the body to help alleviate patient symptoms effectively.
What is Trevi Therapeutics' mission statement?
Trevi Therapeutics' mission is to transform the treatment landscape for patients with chronic and severe diseases through the development of innovative and effective therapies. The company is committed to addressing unmet medical needs and improving the quality of life for patients.
What regulatory approvals has Trevi Therapeutics obtained?
As a clinical-stage biopharmaceutical company, Trevi Therapeutics is actively working to secure regulatory approvals for its product candidates. The company submits applications and data to the Food and Drug Administration (FDA) and other regulatory bodies as part of the drug development process. Approval status will depend on the successful completion of clinical trials.
What role do clinical trials play in Trevi Therapeutics' drug development?
Clinical trials are essential to Trevi Therapeutics' drug development process as they evaluate the safety, efficacy, and dosing of new therapeutic candidates. These trials provide critical data required for regulatory approval and are fundamental to advancing drug candidates from initial discovery through to commercialization.
What stage are Trevi Therapeutics' clinical trials in?
Trevi Therapeutics is in various stages of clinical trials, depending on the product candidate. The company is primarily focusing on Phase 2 and Phase 3 trials to evaluate the safety and efficacy of Haduvio for its designated indications, with results to be analyzed to guide future development.
What types of neurological conditions does Trevi Therapeutics aim to address?
Trevi Therapeutics aims to address various neurological conditions, particularly those that lead to debilitating symptoms such as chronic cough associated with idiopathic pulmonary fibrosis (IPF) and other disorders. The company is committed to finding effective therapeutic options for conditions with significant unmet medical needs.
When did Trevi Therapeutics go public?
Trevi Therapeutics went public on the Nasdaq stock exchange under the ticker symbol TRVI in October 2021. The company raised funds during its initial public offering (IPO) to support the development of its lead product candidate and other clinical initiatives.
Where is Trevi Therapeutics located?
Trevi Therapeutics is headquartered in New Haven, Connecticut. The company operates in a region known for its strong biopharmaceutical and biotechnology ecosystem, allowing it to leverage local expertise and resources.
Who are the key executives at Trevi Therapeutics?
Trevi Therapeutics' leadership team includes experienced professionals from the pharmaceutical and biotech industries. Key executives include the Chief Executive Officer, Co-Founder, and a team of seasoned scientists and business leaders who collectively drive the company's strategic vision and operational execution.
What is the current price of Trevi Therapeutics, Inc. - Common Stock?
The current price of Trevi Therapeutics, Inc. - Common Stock is 5.965
When was Trevi Therapeutics, Inc. - Common Stock last traded?
The last trade of Trevi Therapeutics, Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of Trevi Therapeutics, Inc. - Common Stock?
The market capitalization of Trevi Therapeutics, Inc. - Common Stock is 358.31M
How many shares of Trevi Therapeutics, Inc. - Common Stock are outstanding?
Trevi Therapeutics, Inc. - Common Stock has 60.07M shares outstanding.